Research from enterprise information management services company Iron Mountain and professional services network PwC has shown that the UK is lagging behind other European companies in terms of protecting sensitive information, and responding to risks to that information, and has been for three years in a row.
Although 75% of pharma companies surveyed regarded information as a business asset, firms have been stagnated and could be facing information risks without being fully equipped.
The annual index measures how prepared companies are to address key information trends against a target of 100. For the third year running, UK mid-market firms have fallen short of achieving the European average set by the Netherlands, Hungary, Germany, UK, France and Spain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze